My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 11 723 / https://doi.org/10.3332/ecancer.2017.723

Short Communication

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy

Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, generally low, equally spaced, doses of chemotherapeutic drugs with therapeutic efficacy and low toxicity. This is an effective and low-cost way to treat several types of tumours, including ovarian cancer. Here, we present six cases of advanced ovarian cancer treated with MCT with low doses of cyclophosphamide, which showed clinical response and stable disease.

Keywords: ovarian cancer, metronomic chemotherapy, cyclophosphamide

Loading Article Metrics ... Please wait

Related articles

Case Report: A different surgical approach for cardiophrenic lymph node resection in advanced ovarian cancer

Abstract | Full Article | PDF Published: 16 Nov 2017 / https://doi.org/10.3332/ecancer.2017.780

Clinical Study: Prognostic value of a patient-reported functional score versus physician-reported Karnofsky Performance Status Score in brain metastases

Abstract | Full Article | PDF Published: 10 Nov 2017 / https://doi.org/10.3332/ecancer.2017.779

Clinical Study: Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy

Abstract | Full Article | PDF Published: 24 Oct 2017 / https://doi.org/10.3332/ecancer.2017.776

Conference Report: Highlights from the WIN 2017 Symposium, 26–27 June 2017, Paris, France: ‘Expediting Global Innovation in Precision Cancer Medicine’

Abstract | Full Article | PDF Published: 27 Sep 2017 / https://doi.org/10.3332/ecancer.2017.770

Case Report: Malignant extra-adrenal pelvic paraganglioma in a paediatric patient

Abstract | Full Article | PDF | Spanish Published: 23 Aug 2017 / https://doi.org/10.3332/ecancer.2017.761



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence